Fiverr International Ltd vs Sana Biotechnology Inc — how do they compare? Fiverr International Ltd trades at $11.8 (market cap $404.45M), while Sana Biotechnology Inc trades at $3.29 (market cap $987.94M). The key difference: Sana Biotechnology Inc is far larger — about 2.4× Fiverr International Ltd's market cap. Which is the better fit depends on your goals.
| FVRR | SANA | |
|---|---|---|
Market Cap | $404.45M | $987.94M |
Sector | Industrials | Health |
52-Week High | $26.67 | $5.92 |
52-Week Low | $9.62 | $2.68 |
Enterprise Value | $135.05M | $962.13M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $3.45, down 3.36% today, with a bullish technical signal from moving averages and oscillators. The company shows strong analyst support with 82% buy ratings but faces significant financial challenges including negative ROE of -147.41% and consistent quarterly losses. Recent developments include positive clinical data presentations and a strategic collaboration with Mayo Clinic announced in May 2026.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial cash burn and negative profitability present significant investment risks. The stock's outlook depends heavily on successful clinical development and future revenue generation from its engineered cell therapies.
Trailing returns across standard periods
Latest headlines on both assets
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →